Therapeutic Asset Ratings

3,272 results matching 1 filter

91,564 assets7,904 sponsors3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Selpercatinib Central Nervous System Neoplasm	National Cancer Institute (NCI)	P2	CCC (53)
Selpercatinib Rhabdoid Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Selpercatinib Grade II Glioma	National Cancer Institute (NCI)	P2	CCC (53)
Selpercatinib Refractory Malignant Neoplasm	National Cancer Institute (NCI)	P2	CCC (53)
Selpercatinib Wilms Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Selumetinib Histiocytic Sarcoma	National Cancer Institute (NCI)	P2	CCC (53)
Selumetinib Juvenile Xanthogranuloma	National Cancer Institute (NCI)	P2	CCC (53)
Selumetinib Langerhans Cell Histiocytosis	National Cancer Institute (NCI)	P2	CCC (53)
Selumetinib Malignant Glioma	National Cancer Institute (NCI)	P2	CCC (53)
Selumetinib Her2-Receptor Negative Breast Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Selumetinib Rhabdomyosarcoma	National Cancer Institute (NCI)	P2	CCC (53)
Selumetinib Endometrial Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Selumetinib Ependymoma	National Cancer Institute (NCI)	P2	CCC (53)
Selumetinib Ewing Sarcoma	National Cancer Institute (NCI)	P2	CCC (53)
Selumetinib Fallopian Tube Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Selumetinib Glioma	National Cancer Institute (NCI)	P2	CCC (53)
Selumetinib Hepatoblastoma	National Cancer Institute (NCI)	P2	CCC (53)
Selumetinib Malignant Germ Cell Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Selumetinib Medulloblastoma	National Cancer Institute (NCI)	P2	CCC (53)
Selumetinib Osteosarcoma	National Cancer Institute (NCI)	P2	CCC (53)
Selumetinib Ovarian Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Selumetinib Peripheral Primitive Neuroectodermal Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Selumetinib Rhabdoid Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Selumetinib Soft Tissue Sarcoma	National Cancer Institute (NCI)	P2	CCC (53)
Selumetinib Wilms Tumor	National Cancer Institute (NCI)	P2	CCC (53)

Showing 2026 to 2050 of 3,272 assets

PreviousPage 82 of 131Next